Advanced Oncotherapy Plc Announced, in its results for the year ended 31 December 2019, that loss after tax narrowed to £20.8 (AVO.L) million from £21.1 million. The basic and diluted loss per share stood at 9.83p down from 14.05p. Separately, the company has entered into two financing agreements, providing it access to up to approximately £42 million of additional funding to further the development of the LIGHT system and advance the manufacturing of up to 30 LIGHT systems. #AVO
Login or register to post comments